ArticleBMC medicine2024
Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the Prospective Global GLORIA-AF Registry.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic Evaluations in Electrophysiology in the Last 15 Years: A Systematic Review of the Literature.Reviews in cardiovascular medicine · 2025Pooled it
- Observational
- Navigating Anticoagulation Decisions in Atrial Fibrillation and Frailty Comorbidity.Life (Basel, Switzerland) · 2026Review
- Lactate-to-albumin ratio as a short‑term prognostic biomarker in atrial fibrillation.Journal of cardiothoracic surgery · 2026Article
- Quality of life, care needs and priorities in atrial fibrillation: the impact of number and patterns of comorbidities.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Multimorbidity in Atrial Fibrillation: Impact on Outcomes.Journal of the American Heart Association · 2026Article
- Head-to-head comparison of the ability of the cardiometabolic index and triglyceride-glucose index to predict 3-year major adverse cardiovascular events in patients with atrial fibrillation: insights from a community cohort.Lipids in health and disease · 2026Article
- Application of Artificial Intelligence in the Early Detection and Management of Atrial Fibrillation: State-of-the-art Review.European cardiology · 2026Review
- Turkish Real-Life Atrial Fibrillation in Clinical Practice: 2-Year Clinical Outcomes of the TRAFFIC Study.Anatolian journal of cardiology · 2025Observational
- ETV1 orchestrates a self-reinforcing ERK1/2-RSK3 signaling loop to drive atrial fibrillation pathogenesis: implications for targeted therapy.Scientific reports · 2025Article
- Comorbidity patterns and mortality in atrial fibrillation: a latent class analysis of the EURopean study of Older Subjects with Atrial Fibrillation (EUROSAF).Annals of medicine · 2025Article
- Review
- Sex Differences in Individuals at High Risk of Atrial Fibrillation: A Primary Care Community Cohort Study, 2015-2024.Biomedicines · 2025Article
- Patterns of comorbidities, clinical course, and impact of the ABC Pathway for Integrated Care in patients with atrial fibrillation: a report from the prospective Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) Registry.European heart journal. Quality of care & clinical outcomes · 2025Article
- Cardio-kidney-metabolic complexity in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF registry phase III.Cardiovascular diabetology · 2025Observational
- Comorbidity and medication patterns in atrial fibrillation patients: association with adverse clinical outcomes.Internal and emergency medicine · 2025Article
- The complexity of tackling multimorbidity in atrial fibrillation: how European projects are reshaping our approach to comorbidities.European heart journal open · 2025Article
- Association between fibrinogen-to-albumin ratio and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study using the MIMIC-IV database.European journal of medical research · 2025Article
- The Impact of Comorbidities on Pulmonary Function Measured by Spirometry in Patients After Percutaneous Cryoballoon Pulmonary Vein Isolation Due to Atrial Fibrillation.Journal of clinical medicine · 2025Article
- Multimorbidity increases risk of cardiovascular outcomes in permanent atrial fibrillation: Data from the RACE II study.International journal of cardiology. Heart & vasculature · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical complexity, as the interaction between ageing, frailty, multimorbidity and polypharmacy, is an increasing concern in patients with AF. There remains uncertainty regarding how combinations of comorbidities influence management and prognosis of patients with atrial fibrillation (AF). We aimed to identify phenotypes of AF patients according to comorbidities and to assess associations between comorbidity patterns, drug use and risk of major outcomes.
methodsFrom the prospective GLORIA-AF Registry, we performed a latent class analysis based on 18 diseases, encompassing cardiovascular, metabolic, respiratory and other conditions; we then analysed the association between phenotypes of patients and (i) treatments received and (ii) the risk of major outcomes. Primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). Secondary exploratory outcomes were also analysed.
results32,560 AF patients (mean age 70.0 ± 10.5 years, 45.4% females) were included. We identified 6 phenotypes: (i) low complexity (39.2% of patients); (ii) cardiovascular (CV) risk factors (28.2%); (iii) atherosclerotic (10.2%); (iv) thromboembolic (8.1%); (v) cardiometabolic (7.6%) and (vi) high complexity (6.6%). Higher use of oral anticoagulants was found in more complex groups, with highest magnitude observed for the cardiometabolic and high complexity phenotypes (odds ratio and 95% confidence interval CI): 1.76 [1.49-2.09] and 1.57 [1.35-1.81], respectively); similar results were observed for beta-blockers and verapamil or diltiazem. We found higher risk of the primary outcome in all phenotypes, except the CV risk factor one, with highest risk observed for the cardiometabolic and high complexity groups (hazard ratio and 95%CI: 1.37 [1.13-1.67] and 1.47 [1.24-1.75], respectively).
conclusionsComorbidities influence management and long-term prognosis of patients with AF. Patients with complex phenotypes may require comprehensive and holistic approaches to improve their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.